Young Pharmaceuticals Partners with LAC2βiome for Exclusive U.S. Distribution of Innovative Skincare
In a significant development for the skincare industry, Young Pharmaceuticals, Inc. has announced a new exclusive distribution agreement with LAC2βiome S.r.l., a Milan-based innovative company specializing in microbial-based product solutions. This partnership marks a pivotal step in delivering advanced skincare solutions across the United States.
Young Pharmaceuticals is recognized as a leading provider of physician-dispensed skincare products, focusing on medically formulated solutions that enhance skin health. The collaboration with LAC2βiome aligns perfectly with young's vision, as it integrates cutting-edge scientific technology into skincare. The collaboration promises to elevate the standard of care, particularly among elite plastic surgeons and dermatologists who make up Young’s primary distribution network.
The product line introduced through this partnership will tap into the growing demand for science-based skin health solutions, specifically those utilizing beneficial microbial components. Young is thrilled to offer its new range of products branded as InfiniteSkin™ Microbiome, which will incorporate live beneficial bacteria targeting skin rejuvenation and overall health.
According to John Kulesza, President of Young Pharmaceuticals, "We're excited to introduce the InfiniteSkin™ Microbiome range, especially with the unique mixing technology that delivers live beneficial bacteria directly to the skin. This innovation complements our existing line of medical-grade products and represents a leap toward advanced skincare."
The flagship product of this new line is a patent-pending formula combining Hyaluronic acid and Lactobacilli, delivered through a unique patented mixing ampoule. It will be marketed under the name BiomeAge™, specifically aimed at medical professionals for private labeling. This ensures that the distribution remains within medical offices, thereby maintaining the quality and efficacy that physicians and their patients expect.
LAC2βiome’s CEO and co-founder Lasse Nagell expressed enthusiasm about the alliance, stating, "Our commitment is to provide solution-oriented microbial products suitable for the medical aesthetics market, and partnering with Young allows us to reach a wider audience while adhering to a joint focus on scientifically driven product innovations."
With a mission to educate both healthcare providers and consumers about the benefits of probiotic skincare, the companies plan to utilize Young’s extensive network of over 2,000 dermatologists and plastic surgeons for spreading knowledge on the importance of microbial health in skincare. Luc Monbourquette, director of global business development at LAC2βiome, emphasized that education plays a crucial role in fostering acceptance and understanding of probiotic ingredients in skincare.
Established in 1977 and based in Wethersfield, Connecticut, Young Pharmaceuticals has a rich history of developing effective products for dermatologists. Over the years, the company has adapted to advances in pharmacological science and responded to market needs by formulating innovative aesthetic treatments. Young Pharmaceuticals remains dedicated to offering high-quality medical skincare products globally.
On the other hand, LAC2βiome, founded in 2019, prides itself on its focus on utilizing proprietary, microbial-based ingredients backed by scientific validation. Their B2B model seeks to expand the reach of effective skincare solutions through a growing network of partners worldwide.
As this partnership unfolds, skincare professionals and consumers alike can look forward to an exciting new chapter in medical skincare offerings, one that champions the trend toward microbial solutions that promise to revolutionize how we perceive and treat skin health. This exciting venture aims to set new benchmarks in the field of established dermatology and aesthetic treatments, ultimately benefiting healthcare providers and patients across the board.
Young Pharmaceuticals is recognized as a leading provider of physician-dispensed skincare products, focusing on medically formulated solutions that enhance skin health. The collaboration with LAC2βiome aligns perfectly with young's vision, as it integrates cutting-edge scientific technology into skincare. The collaboration promises to elevate the standard of care, particularly among elite plastic surgeons and dermatologists who make up Young’s primary distribution network.
The product line introduced through this partnership will tap into the growing demand for science-based skin health solutions, specifically those utilizing beneficial microbial components. Young is thrilled to offer its new range of products branded as InfiniteSkin™ Microbiome, which will incorporate live beneficial bacteria targeting skin rejuvenation and overall health.
According to John Kulesza, President of Young Pharmaceuticals, "We're excited to introduce the InfiniteSkin™ Microbiome range, especially with the unique mixing technology that delivers live beneficial bacteria directly to the skin. This innovation complements our existing line of medical-grade products and represents a leap toward advanced skincare."
The flagship product of this new line is a patent-pending formula combining Hyaluronic acid and Lactobacilli, delivered through a unique patented mixing ampoule. It will be marketed under the name BiomeAge™, specifically aimed at medical professionals for private labeling. This ensures that the distribution remains within medical offices, thereby maintaining the quality and efficacy that physicians and their patients expect.
LAC2βiome’s CEO and co-founder Lasse Nagell expressed enthusiasm about the alliance, stating, "Our commitment is to provide solution-oriented microbial products suitable for the medical aesthetics market, and partnering with Young allows us to reach a wider audience while adhering to a joint focus on scientifically driven product innovations."
With a mission to educate both healthcare providers and consumers about the benefits of probiotic skincare, the companies plan to utilize Young’s extensive network of over 2,000 dermatologists and plastic surgeons for spreading knowledge on the importance of microbial health in skincare. Luc Monbourquette, director of global business development at LAC2βiome, emphasized that education plays a crucial role in fostering acceptance and understanding of probiotic ingredients in skincare.
Established in 1977 and based in Wethersfield, Connecticut, Young Pharmaceuticals has a rich history of developing effective products for dermatologists. Over the years, the company has adapted to advances in pharmacological science and responded to market needs by formulating innovative aesthetic treatments. Young Pharmaceuticals remains dedicated to offering high-quality medical skincare products globally.
On the other hand, LAC2βiome, founded in 2019, prides itself on its focus on utilizing proprietary, microbial-based ingredients backed by scientific validation. Their B2B model seeks to expand the reach of effective skincare solutions through a growing network of partners worldwide.
As this partnership unfolds, skincare professionals and consumers alike can look forward to an exciting new chapter in medical skincare offerings, one that champions the trend toward microbial solutions that promise to revolutionize how we perceive and treat skin health. This exciting venture aims to set new benchmarks in the field of established dermatology and aesthetic treatments, ultimately benefiting healthcare providers and patients across the board.
Topics Consumer Products & Retail）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.